Please confirm topic selection

Are you sure you want to trigger topic in your Anconeus AI algorithm?

Please confirm action

You are done for today with this topic.

Would you like to start learning session with this topic items scheduled for future?

Updated: Mar 30 2023

Alkylating Agents

  • Overview
      • Alkylating Agents
      • Mechanism of Action
      • Cyclophosphamide and ifosfamide
      • Crosslinks DNA 
      • Hemorrhagic cytitis and myelosupression
      • Nitrosoureas
      • Crosslinks DNA
      • Dizziness and ataxia
      • Busulfan
      • Alkylates DNA
      • Pulmonary fibrosis and hyperpigmentation
  • Cyclophosphamide and Ifosfamide
    • Mechanism
      • covalently crosslinks DNA
        • at guanine N7 position
        • between strands and within strands
      • requires bioactivation by liver
    • Clinical use
      • non-Hodgkin's lymphoma
      • breast cancer
      • ovarian cancer
      • immunosuppression
    • Toxicity
      • hemorrhagic cystitis
        • prevent with mesna or N-acetylcysteine
          • thiol group binds acrolein, a toxic metabolite
      • myelosuppression
  • Nitrosoureas (Carmustine, Lomustine, Semustine, and Streptozocin)
    • Mechanism
      • crosslinks DNA
      • crosses BBB and enters CNS
      • requires bioactivation
    • Clinical use
      • brain tumors
        • including glioblastoma multiforme
    • Toxicity
      • CNS toxicity
        • dizziness
        • ataxia
  • Busulfan
    • Mechanism
      • alkylates DNA
    • Clinical use
      • CML
        • was gold standard before imatinib was discovered
      • hematopoietic stem cell transplants
        • used for bone marrow ablation
    • Toxicity
      • pulmonary fibrosis
      • hyperpigmentation
Card
1 of 0
Question
1 of 2
Private Note

Attach Treatment Poll
Treatment poll is required to gain more useful feedback from members.
Please enter Question Text
Please enter at least 2 unique options
Please enter at least 2 unique options
Please enter at least 2 unique options